PYC Therapeutics (Australia) Today
| PYC Stock | 1.40 0.05 3.45% |
Performance0 of 100
| Odds Of DistressOver 68
|
PYC Therapeutics is selling for under 1.40 as of the 25th of December 2024; that is 3.45 percent decrease since the beginning of the trading day. The stock's last reported lowest price was 1.4. PYC Therapeutics has more than 68 % chance of experiencing financial distress in the next few years of operation. It also generated negative returns for investors over the last 90 days. PYC Therapeutics has reported 10 for 1 split on 15th of November 2024. The performance scores are derived for the period starting the 25th of November 2024 and ending today, the 25th of December 2024. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | Category Healthcare | Classification Health Care |
PYC Therapeutics is entity of Australia. It is traded as Stock on AU exchange. The company has 466.61 M outstanding shares. More on PYC Therapeutics
Moving together with PYC Stock
| 0.73 | AN3PJ | ANZ Group Holdings | PairCorr |
| 0.61 | ANZ | Australia and New | PairCorr |
| 0.61 | AN3PI | ANZ Group Holdings | PairCorr |
Moving against PYC Stock
PYC Stock Highlights
Most reasonable investors view market volatility as an opportunity to invest at a favorable price or to sell short against a bearish trend. PYC Therapeutics' investment highlights are automatically generated signals that are significant enough to either complement your investing judgment regarding PYC Therapeutics or challenge it. These highlights can help you better understand the position you are entering and avoid costly mistakes.
| CEO Director | GDLP JD | ||||
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, Health Care, Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care (View all Sectors) | ||||
PYC Therapeutics' financial strength is of vital concern to both outside investors and internal stakeholders. Efficiency and cost control are keys to PYC Therapeutics' success, along with its ability to generate sufficient cash flow to pay bills, repay debt, and make a consistent year-to-year profit. | |||||
Debt LevelsPYC Therapeutics can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand PYC Therapeutics' financial leverage. It provides some insight into what part of PYC Therapeutics' total assets is financed by creditors.
| |||||
PYC Therapeutics (PYC) is traded on Australian Securities Exchange in Australia and employs 5 people. PYC Therapeutics is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Small-Cap' category with a current market capitalization of 653.25 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate PYC Therapeutics's market, we take the total number of its shares issued and multiply it by PYC Therapeutics's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities. PYC Therapeutics operates under Biotechnology sector and is part of Health Care industry. The entity has 466.61 M outstanding shares.
PYC Therapeutics has accumulated about 15.57 M in cash with (38.59 M) of positive cash flow from operations.
Check PYC Therapeutics Probability Of Bankruptcy
Ownership AllocationPYC Therapeutics secures a total of 466.61 Million outstanding shares. PYC Therapeutics shows noticeable amount of outstanding shares owned by insiders. An insider is usually defined as a CEO, other corporate executive, director, or institutional investor who own at least 10% of the company's outstanding shares. Since such a large part of the company is owned by insiders, it is advisable to analyze if each of these insiders have been buying or selling the stock in recent months. Please note that no matter how many assets the company retains, if the real value of the company is less than the current market value, you may not be able to make money on it.
Check PYC Ownership Details
PYC Therapeutics Risk Profiles
Although PYC Therapeutics' alpha and beta are two of the key measurements used to evaluate PYC Therapeutics' performance over the market, the standard measures of volatility play an important role as well.
| Mean Deviation | 2.85 | |||
| Standard Deviation | 4.31 | |||
| Variance | 18.56 | |||
| Risk Adjusted Performance | 0.0055 |
PYC Stock Against Markets
Be your own money manager
Our tools can tell you how much better you can do entering a position in PYC Therapeutics without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.Did you try this?
Run Portfolio File Import Now
Portfolio File ImportQuickly import all of your third-party portfolios from your local drive in csv format |
| All Next | Launch Module |
PYC Therapeutics Corporate Management
Elected by the shareholders, the PYC Therapeutics' board of directors comprises two types of representatives: PYC Therapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of PYC. The board's role is to monitor PYC Therapeutics' management team and ensure that shareholders' interests are well served. PYC Therapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, PYC Therapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| MD MBA | Chief Operations | Profile | |
| Glenn Noronha | Chief Officer | Profile | |
| BComm BCom | Company Secretary | Profile | |
| Pr Fletcher | Chief Officer | Profile |
Additional Tools for PYC Stock Analysis
When running PYC Therapeutics' price analysis, check to measure PYC Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy PYC Therapeutics is operating at the current time. Most of PYC Therapeutics' value examination focuses on studying past and present price action to predict the probability of PYC Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move PYC Therapeutics' price. Additionally, you may evaluate how the addition of PYC Therapeutics to your portfolios can decrease your overall portfolio volatility.